Heart failure treatment gets funding

New diagnostic tests to be developed as a result of funding.

Heart Genomics, a biotechnical company that specialises in developing various treatments for heart patients, has received funding that will allow it to further explore clinical trials for new non-invasive methods of diagnosing patients.

The non-profit organisation will use the funding to support its relationship with Florida's research universities, support researchers in their efforts to reach critical milestones and attract private investor capital.

Tests in development by the company include diagnosis through genomic analysis of a patient's heart tissue or blood sample, which can result in a much higher quality of information about patient condition, leading to better treatment decisions.

"This initial round of funding matched by the Institute for the Commercialisation of Public Research will allow us to bring brand new diagnostic tools to doctors treating patients with congestive heart failure," said Joshua Hare, founder of Heart Genomics.

He added that the company is happy to support the progress being made behind the walls of Florida's universities.